{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/lacerations/prescribing-information/clarithromycin/","result":{"pageContext":{"chapter":{"id":"8d7c7214-71fc-5171-9875-f310b20c40cb","slug":"clarithromycin","fullItemName":"Clarithromycin","depth":2,"htmlHeader":"<!-- begin field 705d6b75-78fc-43a5-8522-a76c015e9145 --><h2>Clarithromycin</h2><!-- end field 705d6b75-78fc-43a5-8522-a76c015e9145 -->","summary":"","htmlStringContent":"<!-- begin item eebf498b-50f6-4b99-bda2-a76c015e7650 --><!-- end item eebf498b-50f6-4b99-bda2-a76c015e7650 -->","topic":{"id":"bc1075da-03fb-510a-aafc-42f8402c77bb","topicId":"c455b3ad-86f5-4c2b-a00d-ceb66ba46f46","topicName":"Lacerations","slug":"lacerations","lastRevised":"Last revised in January 2021","chapters":[{"id":"abcb9c5e-8c70-578e-b2f1-2bfe9e0e6dea","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"b3295eac-08d7-597e-9bbf-240c812490a5","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"0f6da996-76f9-5508-aead-4f7d04fc2910","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"3713be7a-1d15-503e-9cdb-6d3afe60f335","slug":"changes","fullItemName":"Changes"},{"id":"d164a0e0-2763-5ec6-8aaa-1f68fe1d381c","slug":"update","fullItemName":"Update"}]},{"id":"e6d917bb-ce9e-58a6-8b13-cf3e389a6aef","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"83820372-5bd1-5e60-a139-cd76615ac683","slug":"goals","fullItemName":"Goals"},{"id":"15606cb7-089f-5a7d-af3f-d4b9c9b0d2be","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"1a9aa28b-0708-5c58-843c-05a09196b471","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"682e483f-7847-5e82-be10-969f896d9533","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"0db2153f-bcb4-5382-9178-92d651a01c4e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"3929f359-184e-53d4-8aca-a4081b967c1a","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"313e7f7d-a625-5b48-a31d-e5f00ca31462","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"0ad26899-0f07-5523-8ea6-17d520df4cc8","slug":"definition","fullItemName":"Definition"},{"id":"e917af1e-ca7f-5ddd-9cb9-1132ce21b4a9","slug":"prevalence","fullItemName":"Prevalence"},{"id":"fe57a056-8e82-56fa-bb79-87f037fb4303","slug":"complications","fullItemName":"Complications"}]},{"id":"e01eac70-aab4-50c3-a90e-7b07194bf1c8","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"c1be68cd-346e-504f-b22f-e8352fc5c3f6","slug":"assessment","fullItemName":"Assessment"}]},{"id":"35a250d2-9a3b-5287-8afa-d73dfc12c39b","fullItemName":"Management","slug":"management","subChapters":[{"id":"9c6adc10-cc7f-5820-b2da-874e89c9b72b","slug":"laceration-low-infection-risk","fullItemName":"Scenario: Laceration - low infection risk"},{"id":"496fa19f-131c-5dd3-8be3-ae041478b608","slug":"laceration-high-infection-risk","fullItemName":"Scenario: Laceration - high infection risk"},{"id":"9204ec1a-d022-5955-9f74-6b4eb51bf9a9","slug":"laceration-infected","fullItemName":"Scenario: Laceration - infected"}]},{"id":"ae2f2d25-ab30-53a1-8eff-d3fb8c5994f9","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"ffdfa8df-e6e7-56b4-99c6-dfe62dda65a2","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"f4667375-a12d-57c4-a82a-192c500b41bb","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"8d7c7214-71fc-5171-9875-f310b20c40cb","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"23d49e6f-7a37-5188-8b3f-6b6fdb671019","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"f3f77580-8498-590e-a7c3-0afbee563567","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"8f912e41-1ff8-5fce-b9b4-6b3524e8f79b","slug":"tetanus-booster","fullItemName":"Tetanus booster"}]},{"id":"b1fc897d-bfab-5305-bcf1-70e0f4598e5a","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"18a38028-bff4-54de-948c-9715f3649589","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"0132c748-edac-513b-a351-59a838b07e61","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"b4b28cd4-4652-528e-aa28-23f341c6a31e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b86d931b-dadb-55a7-92c8-6cdb81ce5d7f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f6695afc-2f21-5bf7-907b-68a0fb3a77c4","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"d4ab79d3-d601-5b9b-b2b5-d3256e138671","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"bc9ca4ec-c56f-5acc-830c-ccf5c31d5f67","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"ae2f2d25-ab30-53a1-8eff-d3fb8c5994f9","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"86770ab0-bd9e-5c01-8a87-e170924e92fe","slug":"licensed-doses","fullItemName":"Licensed doses","depth":3,"htmlHeader":"<!-- begin field cb10f147-c854-4dcf-acc1-a76c015f0ca1 --><h3>What are the licensed doses?</h3><!-- end field cb10f147-c854-4dcf-acc1-a76c015f0ca1 -->","summary":"","htmlStringContent":"<!-- begin item c11978a9-6514-4522-ad10-a76c015f0af9 --><!-- begin field b427504f-da0e-422c-aa86-a76c015f0ca1 --><ul><li><strong>Prescribe clarithromycin for 5–7 days. The licensed oral doses are:</strong><ul><li><strong>Children aged 1 month to 11 years:</strong><ul><li>Body weight up to 8 kg — 7.5 mg/kg twice daily.</li><li>Body weight 8–11 kg — 62.5 mg twice daily.</li><li>Body weight 12–19 kg — 125 mg twice daily.</li><li>Body weight 20–29 kg — 187.5 mg twice daily.</li><li>Body weight 30–40 kg — 250 mg twice daily.</li></ul></li><li><strong>Adults and children aged 12 years and over:</strong><ul><li>For immediate-release formulations — 250 mg twice daily, increased in severe infections to 500 mg twice daily.</li><li>For modified-release formulations — 500 mg once daily, increased in severe infections to 1000 mg once daily.</li></ul></li></ul></li><li><strong>In renal impairment:</strong><ul><li>If estimated glomerular filtration rate (eGFR) is less than 30 mL/minute/1.73 m<sup>2</sup>:<ul><li>Use half normal dose of clarithromycin.</li><li>Avoid <em>Klaricid XL</em><sup>®</sup> or clarithromycin modified release (m/r) preparations.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">BNF 73, 2017</a>]</p><!-- end field b427504f-da0e-422c-aa86-a76c015f0ca1 --><!-- end item c11978a9-6514-4522-ad10-a76c015f0af9 -->","subChapters":[]},{"id":"555d0b02-e3e3-511f-94c5-04ac659415e1","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 407399c6-a871-40bb-bb29-a76c015f2458 --><h3>What are the contraindications and cautions?</h3><!-- end field 407399c6-a871-40bb-bb29-a76c015f2458 -->","summary":"","htmlStringContent":"<!-- begin item ef3b84dd-ceff-47ab-aefd-a76c015f2272 --><!-- begin field 9cb6167c-9623-47d3-b40a-a76c015f2458 --><ul><li><strong>Do not prescribe clarithromycin</strong> <strong>to:</strong><ul><li><strong>People with:</strong><ul><li>Severe hepatic impairment if renal impairment is also present.</li><li>Hypokalaemia.</li><li>A history of QT prolongation or ventricular arrhythmia, including Torsade de Pointes.</li></ul></li><li><strong>Pregnant women </strong>— the manufacturer advises that clarithromycin should be avoided, particularly in the first trimester, unless potential benefit outweighs risk.</li><li><strong>Breastfeeding women </strong>— the manufacturer advises that clarithromycin should be avoided unless potential benefit outweighs risk, as it is present in breast milk.</li></ul></li><li><strong>Prescribe clarithromycin with caution</strong> <strong>in:</strong><ul><li><strong>People with:</strong><ul><li>Coronary artery disease, severe cardiac insufficiency, or bradycardia (less than 50 beats per minute) — increased risk of QT prolongation.</li><li>Impaired hepatic function — clarithromycin is principally excreted by the liver. Hepatic dysfunction, including increased liver enzymes and cholestatic hepatitis (with or without jaundice), has been rarely reported with clarithromycin.</li><li>Moderate to severe renal impairment — if the estimated glomerular filtration rate (eGFR) is less than 30mL/min/1.73 m<sup>2</sup>, use half the normal <a class=\"topic-reference internal-reference\" href=\"/topics/lacerations/prescribing-information/clarithromycin/#licensed-doses\">dose</a> of clarithromycin, and avoid Klaricid XL® (clarithromycin 500 mg prolonged release once daily tablets) or other modified release clarithromycin preparations. </li><li>Conditions that predispose to QT interval prolongation, such as electrolyte disturbances — macrolides can also prolong the QT interval, increasing the risk of Torsades de Pointes arrhythmia. </li><li>Myasthenia gravis — macrolide antibiotics may aggravate weakness symptoms.</li></ul></li><li><strong>People concomitantly receiving:</strong><ul><li>Hepatotoxic drugs — clarithromycin is principally excreted by the liver.</li><li>Drugs that prolong the QT interval — macrolides can also prolong the QT interval. </li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">ABPI Medicines Compendium, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">BNF 73, 2017</a>]</p><!-- end field 9cb6167c-9623-47d3-b40a-a76c015f2458 --><!-- end item ef3b84dd-ceff-47ab-aefd-a76c015f2272 -->","subChapters":[]},{"id":"b72e1f1e-1501-5713-a6f4-019d7f729c16","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 9dd55b01-37fb-4cae-8338-a76c015f3821 --><h3>What are the adverse effects?</h3><!-- end field 9dd55b01-37fb-4cae-8338-a76c015f3821 -->","summary":"","htmlStringContent":"<!-- begin item e5f4c651-f09d-479d-9f21-a76c015f344e --><!-- begin field 478dbc22-4e83-49c4-94e0-a76c015f3821 --><ul><li><strong>Clarithromycin is generally well tolerated and is reputed to cause fewer adverse effects than erythromycin. </strong></li><li><strong>The most common adverse effects are gastrointestinal and include </strong>abdominal pain, nausea, dyspepsia, vomiting and diarrhoea.<ul><li>Consider pseudomembranous colitis (an acute, exudative colitis caused by <em>Clostridium difficile</em>) if a person develops severe diarrhoea during or after treatment with co-amoxiclav. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li><strong>Other common adverse effects include</strong> dysgeusia (metallic taste in the mouth), headache, taste disturbances, insomnia, rash, and hyperhidrosis.</li><li><strong>Uncommon adverse effects include</strong> anorexia, anxiety, blood disorders, chest pain, constipation, dizziness, dry mouth, flatulence, gastritis, glossitis, hepatic dysfunction (including jaundice), leucopenia, malaise; myalgia, stomatitis, tinnitus, tremor, and  QT interval prolongation.</li><li><strong>Ventricular tachycardia and Torsade de Pointes arrhythmia</strong> have also been reported (frequency unknown).</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">BNF 73, 2017</a>]</p><!-- end field 478dbc22-4e83-49c4-94e0-a76c015f3821 --><!-- end item e5f4c651-f09d-479d-9f21-a76c015f344e -->","subChapters":[]},{"id":"1f6b6d3c-fbac-506e-8b70-5bf8eb93da44","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 51b22a35-9ac8-4b35-9325-a76c015f4d0c --><h3>What drug interactions are associated with clarithromycin?</h3><!-- end field 51b22a35-9ac8-4b35-9325-a76c015f4d0c -->","summary":"","htmlStringContent":"<!-- begin item 2480f864-6728-49dd-93ad-a76c015f4b49 --><!-- begin field 472b028b-c10d-4102-9851-a76c015f4d0c --><ul><li><strong>The following drugs are contraindicated (or should be avoided) during treatment with clarithromycin:</strong><ul><li><strong>Apixaban.</strong></li><li><strong>Avanafil </strong>— clarithromycin possibly increases plasma concentration of avanafil.</li><li><strong>Colchicine </strong>— clarithromycin possibly increases risk of colchicine toxicity. Suspend or reduce dose of colchicine; avoid concurrent use in hepatic or renal impairment.</li><li><strong>Domperidone </strong>— clarithromycin increases plasma concentration of domperidone (possible increased risk of ventricular arrhythmias).</li><li><strong>Eletriptan </strong>— clarithromycin increases plasma concentration of eletriptan (risk of toxicity).</li><li><strong>Ergot alkaloids </strong>— increased risk of ergotism when clarithromycin is given with ergot alkaloids. </li><li><strong>Ivabradine </strong>— increased risk of ventricular arrhythmias.</li><li><strong>Ketoconazole </strong>— avoid concurrent use with clarithromycin in people with severe renal impairment. </li><li><strong>Mizolastine </strong>— macrolides possibly inhibit metabolism of mizolastine.</li><li><strong>Pimozide </strong>— increased risk of ventricular arrhythmias.</li><li><strong>Quetiapine </strong>— clarithromycin possibly increases plasma concentration of quetiapine.</li><li><strong>Reboxetine.</strong></li><li><strong>Simeprevir </strong>— clarithromycin possibly increases plasma concentration of simeprevir.</li><li><strong>Simvastatin </strong>— increased risk of myopathy as simvastatin is extensively metabolized by cytochrome P450 enzyme CYP3A4, and clarithromycin is a potent inhibitor of CYP3A4. </li><li><strong>Sirolimus </strong>— clarithromycin increases plasma concentration of sirolimus.</li></ul></li><li><strong>Concurrent treatment with clarithromycin</strong><strong> and the following drugs </strong><strong>should be done with caution </strong>(concurrent use should be monitored; dose adjustments may be indicated):<ul><li><strong>Antidiabetic drugs (including insulin) </strong>— risk of significant hypoglycaemia. Monitor blood glucose levels more regularly, and adjust the dose of the antidiabetic drug accordingly. </li><li><strong>Calcium channel blockers metabolized by CYP3A4 (for example verapamil, amlodipine, and diltiazem) </strong>— risk of hypotension. Plasma concentrations of clarithromycin as well as the calcium channel blockers may increase due to the interaction. Hypotension, bradyarrhythmias, and lactic acidosis have been observed in people taking clarithromycin and verapamil concurrently.</li><li><strong>Carbamazepine </strong>— clarithromycin increases plasma concentration of carbamazepine. Consider reducing dose of carbamazepine.</li><li><strong>Ciclosporin </strong>— clarithromycin inhibits metabolism of ciclosporin (increased plasma concentration).</li><li><strong>Coumarins </strong>— clarithromycin enhances anticoagulant effect of coumarins, such as warfarin. Monitor the international normalized ratio (INR) during concurrent treatment, and adjust the warfarin dose accordingly.</li><li><strong>Midazolam </strong>— clarithromycin inhibits metabolism of midazolam (increased plasma concentration with increased sedation).</li><li><strong>Other statins </strong>— increased risk of myopathy with statins metabolized by cytochrome P450 enzyme CYP3A4.<ul><li>For atorvastatin — avoid concurrent use with clarithromycin if possible. Consider temporarily stopping atorvastatin during short-term treatment with clarithromycin. If concurrent use cannot be avoided, prescribe the lowest starting dose of atorvastatin (10 mg) and advise the person to report any muscle pain, tenderness, or weakness.</li><li>For pravastatin — prescribe clarithromycin with caution and advise the person to seek medical advice if they experience symptoms of myopathy (for example muscle pain, tenderness, or weakness).</li><li>Clinically significant interaction with clarithromycin is not expected for rosuvastatin and fluvastatin. Nevertheless, advise the person to report any muscle pain, tenderness, or weakness.<strong> </strong></li></ul></li><li><strong>Rifabutin </strong>— clarithromycin increases plasma concentration of rifabutin (increased risk of toxicity). Reduce rifabutin dose.</li><li><strong>Ritonavir, saquinavir, telaprevir, and tipranavir:</strong><ul><li>Plasma concentration of clarithromycin increased by ritonavir. Reduce the dose of clarithromycin in people with renal impairment. </li><li>Saquinavir — plasma concentrations of clarithromycin and saquinavir possibly increased when clarithromycin is given with saquinavir (increased risk of ventricular arrhythmias).</li><li>Telaprevir — plasma concentrations of both drugs possibly increased when clarithromycin is given with telaprevir (increased risk of ventricular arrhythmias).</li><li>Tipranavir — plasma concentration of clarithromycin is increased by tipranavir (reduce dose of clarithromycin in renal impairment). Clarithromycin also increases plasma concentration of tipranavir.</li></ul></li><li><strong>Sildenafil </strong>— clarithromycin increases the plasma concentration of sildenafil. Consider reducing initial dose of sildenafil for erectile dysfunction or reduce sildenafil dose frequency to once daily for pulmonary hypertension.</li><li><strong>Tacrolimus </strong>— clarithromycin increases plasma concentration of tacrolimus.</li></ul></li><li><strong>Oral hormonal contraception </strong>— additional contraceptive precautions are <em>not </em>required during or after courses of erythromycin.<ul><li>However, advise women on the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the sections on vomiting and diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li><li><strong>For a complete list of possible drug interactions of clarithromycin, </strong>see the <a data-hyperlink-id=\"d6f6526f-c0d6-49c0-b0ab-a9900000d770\" href=\"http://scribe.clarity.co.uk/www.medicines.org.uk/emc\">electronic Medicines Compendium</a> (eMC) and the <a data-hyperlink-id=\"bc91d376-f72c-4f92-a215-a9900000d789\" href=\"https://bnf.nice.org.uk/\">British National Formulary</a> (BNF).</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">FSRH, 2017</a>]</p><!-- end field 472b028b-c10d-4102-9851-a76c015f4d0c --><!-- end item 2480f864-6728-49dd-93ad-a76c015f4b49 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}